Stock HIKAL HIKAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Hikal Limited NSE India S.E.

Equities

HIKAL

INE475B01022

Market Closed - NSE India S.E.
Other stock markets
 05:13:54 25/06/2024 pm IST 		5-day change 1st Jan Change
346.5 INR +1.15% Intraday chart for Hikal Limited +14.91% +14.00%
24/05 Hikal Limited Approves Board Changes CI
09/05 Transcript : Hikal Limited, Q4 2024 Earnings Call, May 09, 2024

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 62.85 times its estimated earnings per share for the ongoing year.
  • The company appears highly valued given the size of its balance sheet.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
HIKAL LIMITED Stock Hikal Limited
+14.00% 506M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.19% 801B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+47.26% 631B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.09% 359B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+21.92% 337B
B-
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.40% 245B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+3.64% 231B
A+
NOVARTIS AG Stock Novartis AG
+12.98% 219B
B-
AMGEN INC. Stock Amgen Inc.
+10.86% 171B
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.78% 161B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. HIKAL Stock
  4. HIKAL Stock
  5. Ratings Hikal Limited